We have been granted world-wide licenses to commercialize all animal applications of technologies and products developed by pioneers in the field of stem cell and other bioscience fields, supported by university researchers and leading clinical practitioners in veterinarian medicine.

Photo-Activated Adipose Stem Cell and PRP Technology. (“PA ASC/PRP Technology”)

A proprietary method and process for collecting and activating both Adipose Stem Cells and PRP

The Company’s parent company, Tithon Biotech, pursuant to an Exclusive World Wide License and Supply Agreement entered into with Adistem (the “AdiStem License”), obtained the exclusive worldwide right to market and sell, as well as sublicense the animal applications of Adipose Stem Cell (“ASC”) and Platelet Rich Plasma (“PRP”) Technology, including lecithin growth medium and Adilight-2 products currently being sold under an Exclusive Master Distribution Agreement (the “EMDA”) by MediVet, Pty. Ltd. Simultaneous with the grant of the AdiStem License, AdiStem assigned all further rights including all future compensation under the EMDA to Tithon Biotech. In October of 2015, Tithon Biotech granted the Company the exclusive worldwide right to market and sell the Photo-Activated ASC and PRP Kits and Adilight-2 pursuant to a Sub-License and Supply Agreement and further assigned all future rights and obligations under the EMDA.

Peripheral Blood Derived Pluripotent Stem Cell Technology (PBD-PSC Technology”)

A proprietary method and process  for collecting from peripheral blood a novel newly discovered pluripotent stem cell, which early clinical testing indicates holds promise in treating a number of degenerative conditions

Tithon Biotech, pursuant to a Technology Transfer Agreement, was assigned all of the rights, titles and interests anywhere in the world in including, but not limited to all Intellectual Property Rights relating to the body of technology, inventions, works, concepts, methods, ideas, processes and know-how respecting a parathyroid hormone receptor positive pluripotent stem cells (“PBD-PSC”) derived from peripheral blood, useful in both regenerative and therapeutic treatment of animals (the “PBD-PSC Technology”). Tithon Biotech granted the Company the exclusive worldwide right to market and sell all animal applications of the PBD-PSC Technology pursuant to a License and Supply Agreement entered into with Tithon Biotech.

Animal Antigen-Specific Immunotherapy

A line of proprietary products currently under development based on what has been labeled Antigen Specific Immunotherapy Technology, which have been shown useful in addressing various autoimmune disorders.

Under the worldwide exclusive sub-license and supply agreement with Tithon Biotech, the Company, with the assistance of Paspa Pharmaceutical Pty Ltd  will continue the development and commercialization of the animal applications of Antigen-Specific Immunotherapy Technology into various drugs registered by the FDA as an OTC drug, approved as an orally administered liquid or spray. Antigen-Specific Immunotherapy Technology employs a process developed by Paspa, in which various proprietary immortal  tissue cell lines (“Proprietary Tissue Cell Lines”) are processed using a proprietary method, also developed and tested by Paspa, in which the live cells of a particular tissue line are lysed through use of ultrasound, thereby destroying the living cell and rendering the cell’s membrane fragments, while also sterilizing the liquid containing the fragmented cells. The rendered cell membranes are then potentized” through homeopathic succussion/dilution techniques by a licensed FDA-cGMP approved manufacturing facility, for delivery, as what is known as a “sarcode” in “isopathy or “iso-organotherapy,” a subset of homeopathy, and sold as an FDA registered OTC drug.

Paspa, through both laboratory and clinical testing, has demonstrated that these various Proprietary Tissue Cell Lines, as processed into an isopathic sarcode liquid or spray, when administered over a recommended period of time, evidence a dampening down of the body’s own antibody aggression against the body’s own tissues targeted by the specific Proprietary Tissue Cell Line rendered into an isopathic sarcode, thereby also converting the body’s aggressive immune response cells, attacking the bodies self-tissue, into cells capable of protecting against disease (i.e. immune tolerance).

Tissue Cell Lines for Therapeutic Uses

The therapeutic use of glandulars in medicine dates back to antiquity. However, the use of dynamised healthy organ and glandular tissue and their secretions was first introduced into homeopathic practice by Constantine Hering, MD in 1834. They are listed in the HPUS as Class L Sarcodes and are used by practitioners in all potencies from the lowest to the highest and across all potency scales, often prescribed constitutionally. Organotherapy remedies, by contrast, although made in the same manner, are typically utilized in low centesimal potencies for the specific purpose of regulating the function of their homologous tissue. Much of what we know regarding the practical application of Organotherapy comes from the work of Drs. Max Tétau and Claude Bergeret of France2. Their research showed that when these tissues were potentized to 4C and 5C they exerted a stimulatory effect, 7C was more balancing and 9C inhibitory.

Organotherapy is, in its simplest explanation, the repair of the  organs to function properly, and is based on two fundamental laws:

  1. Identical organs: When a diseased organ is present, an identical healthy organ extract is administered to rectify the organ.
  2. Activity by potency: Organ medicine is used to strengthen organs, glands, and tissues weakened by toxins. A low potency is used to stimulate an under active organ, gland, or tissue.

This specialized treatment of disease uses preparations derived from organs or glandular extracts to regulate and correct function of organs and bodily systems on a cellular level.

Organotherapy is postulated to stimulate organ functions, depending on the tissues, while helping to prevent antibodies from being formed against the organs. Enzymes and nucleic acids can be used in such treatments as well. The principle is that organs can recognize the right cells, which usually start reproducing once inside the liver or pancreas, for example.